Member Info for 86KB

Thats quite sad Peter if you sold well done to you but no need to start posting rubbish thereafter. Those who have done research know they have warrants at 2p which will bring in £1.89mil so need for a placing.

Expect some huge interest this week, conference ongoing this week. Could we see New major investors could be taking position?

Tiger it is probably warrants or Lanstead selling their last lot. Tr1 confirming they are out and it will run.

They were invited so clearly there is an interest. IMM have something to showcase and the industry wants to know more. There are already discussions taking place.

This event is by invitation only and invitations are not transferable. Contact your J.P. Morgan representative for more information.

The 43rd Annual Healthcare Conference will take place on January 13-16, 2025 in San Francisco, CA.

This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

Conference is from 13-16th, so showcase probably from 11th-12?

Have to bear in mind that these have moved from 1.2s and would expect profit takers and consolidation to take place, which is fine but these are worth more than current prices. Its going to be a bumpy ride but they should go much higher. Opportunity to get the dip imo.

Final hour should see us back into 4s shortly, close near days high will be great.

Imm highlighted in their rns about eleven $1bn+ licensing deals for immunology assets and that Immunology and Autoimmune drug assets are becoming very highly sought by the leading BioPharma companies.

Global BioPharma companies have shown an interest in autoimmune diseases demonstrated within P140 technology platform.

Biotech company peers are valued at least 100x higher on average by the

markets

▪ Biotech’s with similar stage products valued ~£550m-1.4 billion

▪ ImmuPharma ~£17m

SALES POTENTIAL OF ~$4bn

Xviolet think you need to read through the rns, they have had significant interest, the company are talking about licensing agreements could potentially be £1billion+, the autoimmune disease therapy market is in huge demand and expected to grow. They will probably get upfront payments, they even have warrants. Do some research and know they wouldn't need to raise.

Final flush before a strong close ready for next week.

Consolidating well here, some nice delayed trades there whether they are buys, lanstead offloading or warrants holding pretty well and gearing up for the next wave.

Bear in mind there are only 416million shares in issue at the moment. Almost traded half of that in 2 days.

We have had pretty good volume, there are 94,545,455 warrants at 2p and lanstead had 28744325 shares left to sell. Total 123,289,780. So say we do x 4 that amount over the week then will clear easily.

There are some warrants at 5p which would bring some funds in not as much as the 2p ones. But would add £150k to the pot plus the £1.89m would give over £2mil in funds.

Another strong afternoon like yesterday

We know there are warrants at 2p which will bring £1.89mil so doubt there will be a placing imo. Plus after the results they had I doubt they will place down these levels especially when they are in discussions for deals which would possibly give them upfront payments.

Remember this stock is sets, so price will be all over the place. We just had significant news it was never going to be an easy ride up. So some will sell only to find few moments later its gone much higher. Overall the trend is up and with the conference/showcase next week it will be a bumpy ride but will be much higher.

"we are progressing discussions as we move to establish global licensing agreements"

If they get $1bn+ licensing deal with global BioPharma companies that have an interest in P140 technology then this will go on mad run to pounds

Its this that tells you where it should be heading.

The JP Morgan conference and Biotech Showcase are annual premier partnering events, designed to provide biotechnology companies with the opportunity to present to and connect with global Biopharma companies and investors.

The advances made by ImmuPharma with the P140 program, particularly in the latter part of 2024, have led to significant interest from leading Biopharmaceutical companies and we are progressing discussions as we move to establish global licensing agreements.

There have been eleven $1bn+ licensing deals for immunology assets across the BioPharma industry from 2023 to late September 2024. The current trend suggests that Immunology and Autoimmune drug assets are becoming very highly sought by the leading BioPharma companies.

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma said: "Attending and taking meetings at both the JP Morgan conference and the Biotech Showcase offers the opportunity to continue discussions across our whole unique portfolio and specifically with global BioPharma companies that have an interest in autoimmune diseases demonstrated within our P140 technology platform. Our focus remains on track to establish global partnering opportunities across all of our programs."